Biofortuna Reaches Key Milestones for ReadyPlex™
News Oct 04, 2016
Biofortuna Ltd has successfully achieved key milestones in the development of its new blood group genotyping product family – ReadyPlex™. This breakthrough has released the second tranche of its 2015 funding – totalling £1.5m – which will be used for final development and commercialisation of this innovative product line. The ReadyPlex range is aimed at the transfusion market, and will offer rapid genomic analysis of erythrocyte blood groups, human platelet antigens (HPAs), human neutrophil antigens (HNAs) and coagulation polymorphisms.
A product design freeze has now been achieved, and this additional funding – supported by all the company’s current investors, including Foresight VCTs, Catapult Ventures, Enterprise Ventures, Merseyside Special Investment Fund, private investors and management – will enable verification and validation of the product family as it moves towards clinical trials. In addition, the funding will be used to increase the capabilities and production capacity of Biofortuna’s manufacturing and development contract services division, helping to meet the demand of current and future contracts.
Dr Simon Douglas, Biofortuna CEO, said: “The new investment will be used to increase the portfolio of tests currently offered by Biofortuna. These new funds and the confidence of all of our investors shows the potential of Biofortuna as a leading diagnostic kit provider, as well as a world-class contract service manufacturer.”
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Gene-edited Pigs are Resistant to Billion-dollar VirusNews
Scientists have produced pigs that can resist one of the world’s most costly animal diseases, by changing their genetic code. Tests with the virus – called Porcine Reproductive and Respiratory Syndrome, or PRRS – found the pigs do not become infected at all. The animals show no signs that the change in their DNA has had any other impact on their health or wellbeing.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE